Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial

Mirahmadizadeh et al., Respirology, doi:10.1111/resp.14318
Jun 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ventilation, 24mg 67% Improvement Relative Risk Ventilation, 12mg 33% Hospitalization, 24mg 46% primary Hospitalization, 12mg 27% primary Recovery, 24mg 39% Recovery, 12mg 31% Recovery time, 24mg 0% no CI Recovery time, 12mg 0% no CI Ivermectin  Mirahmadizadeh et al.  EARLY TREATMENT  DB RCT Is early treatment with ivermectin beneficial for COVID-19? Double-blind RCT 261 patients in Iran (April - May 2021) Lower ventilation (p=0.37) and hospitalization (p=0.22), not sig. c19ivm.org Mirahmadizadeh et al., Respirology, Jun 2022 Favorsivermectin Favorscontrol 0 0.5 1 1.5 2+
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19ivm.org
RCT with 131 24mg ivermectin, 130 12mg ivermectin, and 130 placebo patients, showing no significant differences in outcomes. Lower ventilation and hospitalization was seen with treatment, in a dose-dependent manner, but not reaching statistical significance with the small number of events.
This is the 39th of 51 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000015.
This is the 88th of 104 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
risk of mechanical ventilation, 66.9% lower, RR 0.33, p = 0.37, treatment 1 of 131 (0.8%), control 3 of 130 (2.3%), NNT 65, 24mg.
risk of mechanical ventilation, 33.3% lower, RR 0.67, p = 1.00, treatment 2 of 130 (1.5%), control 3 of 130 (2.3%), NNT 130, 12mg.
risk of hospitalization, 45.9% lower, RR 0.54, p = 0.22, treatment 6 of 131 (4.6%), control 11 of 130 (8.5%), NNT 26, 24mg, primary outcome.
risk of hospitalization, 27.3% lower, RR 0.73, p = 0.63, treatment 8 of 130 (6.2%), control 11 of 130 (8.5%), NNT 43, 12mg, primary outcome.
risk of no recovery, 38.9% lower, RR 0.61, p = 0.27, treatment 8 of 131 (6.1%), control 13 of 130 (10.0%), NNT 26, day 28, 24mg.
risk of no recovery, 30.8% lower, RR 0.69, p = 0.50, treatment 9 of 130 (6.9%), control 13 of 130 (10.0%), NNT 32, day 28, 12mg.
recovery time, no change, relative time 1.00, treatment 131, control 130, 24mg.
recovery time, no change, relative time 1.00, treatment 130, control 130, 12mg.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mirahmadizadeh et al., 23 Jun 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Iran, peer-reviewed, 12 authors, study period 9 April, 2021 - 20 May, 2021, dosage 24mg single dose, 12mg and 24mg arms.
This PaperIvermectinAll
{ 'indexed': {'date-parts': [[2022, 6, 24]], 'date-time': '2022-06-24T01:41:33Z', 'timestamp': 1656034893495}, 'reference-count': 35, 'publisher': 'Wiley', 'license': [ { 'start': { 'date-parts': [[2022, 6, 23]], 'date-time': '2022-06-23T00:00:00Z', 'timestamp': 1655942400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'http://onlinelibrary.wiley.com/termsAndConditions#vor'}, { 'start': { 'date-parts': [[2022, 6, 23]], 'date-time': '2022-06-23T00:00:00Z', 'timestamp': 1655942400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'http://doi.wiley.com/10.1002/tdm_license_1.1'}], 'funder': [ { 'DOI': '10.13039/501100004320', 'name': 'Shiraz University of Medical Sciences', 'doi-asserted-by': 'publisher', 'award': ['99‐7850']}], 'content-domain': {'domain': ['onlinelibrary.wiley.com'], 'crossmark-restriction': True}, 'DOI': '10.1111/resp.14318', 'type': 'journal-article', 'created': {'date-parts': [[2022, 6, 24]], 'date-time': '2022-06-24T00:59:40Z', 'timestamp': 1656032380000}, 'update-policy': 'http://dx.doi.org/10.1002/crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Efficacy of single‐dose and double‐dose ivermectin early treatment in preventing progression to ' 'hospitalization in mild\n' ' <scp>COVID</scp>\n' ' ‐19: A multi‐arm, parallel‐group randomized, double‐blind, placebo‐controlled trial', 'prefix': '10.1111', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-2259-4984', 'authenticated-orcid': False, 'given': 'Alireza', 'family': 'Mirahmadizadeh', 'sequence': 'first', 'affiliation': [ { 'name': 'Non‐communicable Diseases Research Center Shiraz University of ' 'Medical Sciences Shiraz Iran'}]}, { 'ORCID': 'http://orcid.org/0000-0001-6322-7876', 'authenticated-orcid': False, 'given': 'Ali', 'family': 'Semati', 'sequence': 'additional', 'affiliation': [ { 'name': 'Non‐communicable Diseases Research Center Shiraz University of ' 'Medical Sciences Shiraz Iran'}]}, { 'ORCID': 'http://orcid.org/0000-0001-6567-5306', 'authenticated-orcid': False, 'given': 'Alireza', 'family': 'Heiran', 'sequence': 'additional', 'affiliation': [ { 'name': 'Non‐communicable Diseases Research Center Shiraz University of ' 'Medical Sciences Shiraz Iran'}]}, { 'ORCID': 'http://orcid.org/0000-0003-2724-039X', 'authenticated-orcid': False, 'given': 'Mostafa', 'family': 'Ebrahimi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Communicable Diseases Control Center Shiraz University of ' 'Medical Sciences Shiraz Iran'}]}, { 'ORCID': 'http://orcid.org/0000-0001-9951-8341', 'authenticated-orcid': False, 'given': 'Abdolrasool', 'family': 'Hemmati', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Health Affairs Shiraz University of Medical ' 'Sciences Shiraz Iran'}]}, { 'ORCID': 'http://orcid.org/0000-0002-1435-3996', 'authenticated-orcid': False, 'given': 'Mohammadreza', 'family': 'Karimi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Health Affairs Shiraz University of Medical ' 'Sciences Shiraz Iran'}]}, { 'ORCID': 'http://orcid.org/0000-0001-8474-8822', 'authenticated-orcid': False, 'given': 'Souzan', 'family': 'Basir', 'sequence': 'additional', 'affiliation': [{'name': 'Shiraz University of Medical Sciences Shiraz Iran'}]}, { 'ORCID': 'http://orcid.org/0000-0002-0199-3230', 'authenticated-orcid': False, 'given': 'Marjan', 'family': 'Zare', 'sequence': 'additional', 'affiliation': [ { 'name': 'Non‐communicable Diseases Research Center Shiraz University of ' 'Medical Sciences Shiraz Iran'}]}, { 'ORCID': 'http://orcid.org/0000-0001-5516-5177', 'authenticated-orcid': False, 'given': 'Antonio', 'family': 'Charlys da Costa', 'sequence': 'additional', 'affiliation': [ { 'name': 'Institute of Tropical Medicine, School of Medicine University of ' 'São Paulo São Paulo Brazil'}]}, { 'ORCID': 'http://orcid.org/0000-0003-4233-9275', 'authenticated-orcid': False, 'given': 'Mohammad', 'family': 'Zeinali', 'sequence': 'additional', 'affiliation': [ { 'name': 'National Zoonoses Control Department Ministry of Health and ' 'Medical Education Tehran Iran'}]}, { 'ORCID': 'http://orcid.org/0000-0001-7689-9866', 'authenticated-orcid': False, 'given': 'Maryam', 'family': 'Sargolzaee', 'sequence': 'additional', 'affiliation': [ { 'name': 'Communicable Diseases Control Center Ministry of Health and ' 'Medical Education Tehran Iran'}]}, { 'ORCID': 'http://orcid.org/0000-0001-5313-1352', 'authenticated-orcid': False, 'given': 'Owrang', 'family': 'Eilami', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Family Medicine and Infectious Diseases Shiraz ' 'University of Medical Sciences Shiraz Iran'}]}], 'member': '311', 'published-online': {'date-parts': [[2022, 6, 23]]}, 'reference': [ { 'key': '#cr-split#-e_1_2_10_2_1.1', 'unstructured': 'World Health Organization.COVID‐19: Clinical Care. Therapeutics and ' 'COVID‐19: Living Guideline. [updated 2021 Sep 25'}, { 'key': '#cr-split#-e_1_2_10_2_1.2', 'unstructured': 'cited 2021 Sep 28]. Available ' 'from:https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.2'}, {'key': 'e_1_2_10_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/d41586-020-02360-y'}, {'key': 'e_1_2_10_4_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/d41586-021-02783-1'}, {'key': 'e_1_2_10_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/d41586-021-03074-5'}, { 'key': 'e_1_2_10_6_1', 'unstructured': 'Bloomberg.Remdesivir Averts Hospitalization in Study of High‐Risk ' 'Patients.2021Sep 22 [cited 2021 Nov 27]. Available ' 'from:https://www.bloomberg.com/news/articles/2021-09-22/remdesivir-averts-hospitalization-in-study-of-high-risk-patients'}, {'key': 'e_1_2_10_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/d41586-021-02054-z'}, {'key': 'e_1_2_10_8_1', 'doi-asserted-by': 'publisher', 'DOI': '10.2183/pjab.87.13'}, { 'key': 'e_1_2_10_9_1', 'unstructured': 'World Health Organization.World Health Organization Model List of ' 'Essential Medicines: 21st List 2019.Geneva:World Health ' 'Organization;2019[cited 2021 Sep 19]. Available ' 'from:https://apps.who.int/iris/bitstream/handle/10665/325771/WHO-MVP-EMP-IAU-2019.06-eng.pdf'}, {'key': 'e_1_2_10_10_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.pt.2017.02.004'}, {'key': 'e_1_2_10_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/srep23138'}, { 'key': 'e_1_2_10_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2013.10.004'}, { 'key': 'e_1_2_10_13_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2013.06.002'}, {'key': 'e_1_2_10_14_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1042/BJ20120150'}, { 'key': 'e_1_2_10_15_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2012.06.008'}, { 'key': 'e_1_2_10_16_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2020.104760'}, {'key': 'e_1_2_10_17_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/jac/dks147'}, { 'key': 'e_1_2_10_18_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.antiviral.2020.104787'}, {'key': 'e_1_2_10_19_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/v13060989'}, {'key': 'e_1_2_10_20_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2021.3071'}, { 'key': 'e_1_2_10_21_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s13063-020-04813-1'}, {'key': 'e_1_2_10_22_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/jac/dkz524'}, { 'key': 'e_1_2_10_23_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s43440-020-00195-y'}, { 'key': '#cr-split#-e_1_2_10_24_1.1', 'unstructured': 'World Health Organization.COVID‐19 Therapeutic Trial Synopsis Draft. ' '[updated 2020 Feb 18'}, { 'key': '#cr-split#-e_1_2_10_24_1.2', 'unstructured': 'cited 2021 Sep 19]. Available ' 'from:https://www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis'}, { 'issue': '1', 'key': 'e_1_2_10_25_1', 'first-page': '63', 'article-title': 'A comparative study on ivermectin‐doxycycline and ' 'hydroxychloroquine‐azithromycin therapy on COVID‐19 patients', 'volume': '5', 'author': 'Chowdhury A', 'year': '2021', 'journal-title': 'EJMO'}, { 'key': 'e_1_2_10_26_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/s0895-4356(98)00138-3'}, {'key': 'e_1_2_10_27_1', 'doi-asserted-by': 'publisher', 'DOI': '10.18433/jpps32105'}, { 'key': 'e_1_2_10_28_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ijantimicag.2021.106516'}, { 'key': 'e_1_2_10_29_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.eclinm.2021.100959'}, { 'key': '#cr-split#-e_1_2_10_30_1.1', 'unstructured': 'World Health Organization.WHO Advises that Ivermectin Only Be Used to ' 'Treat COVID‐19 Within Clinical Trials. [updated 2021 Mar 31'}, { 'key': '#cr-split#-e_1_2_10_30_1.2', 'unstructured': 'cited 2021 Sep 19]. Available ' 'from:https://www.who.int/news-room/feature-stories/detail/who-advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials'}, { 'key': 'e_1_2_10_31_1', 'unstructured': 'Centers for Disease Control and Prevention (CDC).Rapid Increase in ' 'Ivermectin Prescriptions and Reports of Severe Illness Associated with ' 'Use of Products Containing Ivermectin to Prevent or Treat COVID‐19. ' '[updated 2021 Aug 26; cited 2021 Sep 19]. Available ' 'from:https://emergency.cdc.gov/han/2021/han00449.asp'}, { 'key': '#cr-split#-e_1_2_10_32_1.1', 'unstructured': 'Google News.Coronavirus (COVID‐19). [updated 2021 Sep 27'}, { 'key': '#cr-split#-e_1_2_10_32_1.2', 'unstructured': 'cited 2021 Oct 2]. Available ' 'from:https://news.google.com/covid19/map?hl=fa&state=7&mid=%2Fm%2F03shp'}], 'container-title': 'Respirology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1111/resp.14318', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/full-xml/10.1111/resp.14318', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://onlinelibrary.wiley.com/doi/pdf/10.1111/resp.14318', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 6, 24]], 'date-time': '2022-06-24T01:00:00Z', 'timestamp': 1656032400000}, 'score': 1, 'resource': {'primary': {'URL': 'https://onlinelibrary.wiley.com/doi/10.1111/resp.14318'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 6, 23]]}, 'references-count': 35, 'alternative-id': ['10.1111/resp.14318'], 'URL': 'http://dx.doi.org/10.1111/resp.14318', 'relation': {}, 'ISSN': ['1323-7799', '1440-1843'], 'subject': ['Pulmonary and Respiratory Medicine'], 'container-title-short': 'Respirology', 'published': {'date-parts': [[2022, 6, 23]]}, 'assertion': [ { 'value': '2021-12-08', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2022-05-13', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2022-06-23', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit